Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company’s lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Briquilimab's Promise | Explore Jasper Therapeutics' lead product, briquilimab, and its potential to revolutionize treatment for chronic urticaria, with projected peak sales of $500-550 million. |
Clinical Milestones | Delve into Jasper's ongoing trials, including the BEACON and SPOTLIGHT studies, with key data readouts expected to significantly impact the company's valuation. |
Market Positioning | Learn how Jasper aims to differentiate briquilimab from competitors like Celldex's barzolvolimab, potentially offering improved safety and dosing convenience. |
Analyst Outlook | Discover why analysts set price targets ranging from $63 to $86, reflecting optimism about Jasper's potential in the mast cell-mediated disease market. |
Metrics to compare | JSPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipJSPRPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.6x | −1.3x | −0.6x | |
PEG Ratio | −0.05 | −0.01 | 0.00 | |
Price/Book | 1.2x | 0.9x | 2.6x | |
Price / LTM Sales | - | 12.1x | 3.1x | |
Upside (Analyst Target) | - | 418.1% | 51.7% | |
Fair Value Upside | Unlock | 18.1% | 7.5% | Unlock |